Skip Navigation

Annals of Oncology 2005 16(4):523-524; doi:10.1093/annonc/mdi135
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bernhard, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bernhard, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Editorial

Timing of quality of life assessment in cancer clinical trials: fine tuning remains a challenge

J. Bernhard, PD PhD

Institute of Medical Oncology, Inselspital Bern and Swiss Institute for Applied Cancer Research, Bern; (Email: jbernhard@sakk.ch)

The first 10% of the full text of this article appears below.

Over the past decades, hundreds of different quality of life-related measures have been published, including generic (general) and disease or treatment-specific measures to be used in cancer patients. ‘Just give me the best quality of life questionnaire’ is a familiar request to those involved in quality of life research, especially those collaborating with clinicians who conduct clinical trials. This simple question exposes a morass of complexity. Usually there is at least some empirical evidence to assist the choice, but that depends critically upon the research question and the corresponding study design.

In a recent phase-III trial by . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
T. Tanvetyanon
Reply to the article "The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer" by K. P. Weinfurt et al. (Ann Oncol 2005; 16: 579-584)
Ann. Onc., October 1, 2005; 16(10): 1712 - 1713.
[Full Text] [PDF]